As­traZeneca cheers a suc­cess for PhI­II ben­ral­izum­ab study; TP rais­es $45M for can­cer drug

→ As­traZeneca says that its Phase III ZON­DA study of ben­ral­izum­ab hit the pri­ma­ry end­point, al­low­ing asth­ma pa­tients to re­duce the use of steroids while main­tain­ing con­trol of the dis­ease. “Ben­ral­izum­ab showed an im­pres­sive clin­i­cal ef­fi­ca­cy by re­duc­ing ex­ac­er­ba­tions rate by up to 70% at the same time en­abling pa­tients with se­vere asth­ma to sig­nif­i­cant­ly low­er their pred­nisone dose and main­tain their lung func­tion,” said Para­meswaran Nair, pro­fes­sor of res­pi­ra­to­ry med­i­cine at Mc­Mas­ter Uni­ver­si­ty in Hamil­ton, Cana­da and the lead in­ves­ti­ga­tor of the tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER